Simon Skjøde Jensen work email
- Valid
- Valid
Simon Skjøde Jensen personal email
With a strong experience in the life science field, I am driven by the process of developing new and more efficient treatments within therapeutics and preventive technologies. I have been CEO of MonTa Biosciences since 2014 when I co-founded the company as a spin-out from DTU Health. I have experience with management of start-up companies, negotiating license agreements, raising investment and entrepreneurship in the biotech field, with scientific expertise in the oncology and immunology field. During this exiting process I have gained skills in many different fields beyond science and technology, including strategy, competitor and marked overview, clinical and regulatory design and evaluation and exploring clinical opportunities, identify and communicate with relevant venture and corporate venture partners, prepare business and development plans and much more. I have lead and closed two licensing agreements and closed four investment rounds with venture or private investors and are currently leading partnership discussions and out-licensing opportunities with major pharma companies.Specialties:• CEO in start-up biotech company• Taken an early stage project to the clinical stage • Experienced and responsible for taking an early asset through CMC, toxicology and regulatory process to clinical testing• Negotiated and closed two licensing deals• Raised and negotiated four investment rounds for MonTa Biosciences• 20 years experience from biotech/pharma• People management• Track record of good collaborative skills with international partners• Management of grants and establishment of strategic projects• Strong commitment and ability to meet deadlines• Creative, organized and structured • Driver of innovation and development of new technologies• A positive and open mind-set with sound flexibility• Experience in business development, licensing deals, partnership and out-licensing discussions• A dedicated, profound, hardworking team-player with a professional and competitive spirit• A sympathetic and acknowledging colleague with good empathy• Patent inventor and author on peer reviewed publications
-
Chief Executive OfficerMonta Biosciences 2014 - PresentKongens Lyngby, Capital Region, DkAs CEO of MonTa Biosciences I have developed the company from a start-up to a full-blown clinical stage biotech company. I have enjoyed the exiting journey with a sharp learning curve of taking our technology from bench to bedside, and led the lead selection process, preclinical development, CMC activities and GLP tox studies and completing our Clinical Trial Protocol. We have now been running our clinical trial for 3 years with clinical sites in Belgium, Spain and Denmark, and dosed more than 40 patients and learned a lot about our lead drug MBS8. I have closed license agreements and five rounds of investments to MonTa, the most recent a series A investment to secure development and completion of our phase I clinical trial to find the optimal way to treat patients with MBS8. As CEO of MonTa Biosciences I am focused on creating value and bring our lead candidate timely to patients in need. The role as CEO involves management of our strong team and development of the company, high level overview of CMC activities, pharmacology studies, biomarker and regulatory strategy and process, business development, finance and contracts, intellectual property strategy and licensing. With accumulating clinical data we are in the strategic process on further clinical development which is very exciting and challenging considering the multitude of opportunities for clinical development in the space between unmet medical needs, current standard of care, commercial opportunities and the competitive space in the given indication on e.g. patient recruitment. Please visit www.montabiosciences.com -
Senior Project ManagerDtu Health Tech Aug 2014 - Dec 2016Kgs. Lyngby, Danmark, DkI was key in the innovative process of spinning out a new type of cancer immunotherapy technology from DTU Nanotech to establish the biotech Company MonTa Biosciences. Tasks included working with innovation, collaborations, setting up strategic research partnerships, advisors and supervisor for stakeholders, negotiating contracts and license agreements, communicating, presenting and negotiating with investors, establishing BoD, negotiating and handling investment process including contract discussions and execution, attraction of soft funding, reporting to granting bodies, and fianlly management of RnD-projects to develop the cancer immunotherapy technology to obtain PoC. -
Steering Group Manager, Centre For Regulatory T-CellsBioneer A/S 2012 - 2014Hørsholm, DkManagement of the steering Group for the Innovation Consortium "Treg-Centre" involving major Pharma and biotech Companies, and leading university partners. -
Group Leader, Immune TargetingBioneer A/S 2005 - 2014Hørsholm, Dk• People management of research scientists, technicians and students• Responsible for establishment of projects with national and international partners, secure appropriate project delivery and reporting to Danish and EU authorities• Customer related activities involving marketing material, presentations, meetings, quotations, accomplish assignments, datahandling and interpretation, preparation of final reports • Grant proposals, applications, implementation and reporting• Writing patents and particitate in the filing process• Prepare manuscripts and publications2011-13: Awarded an EU grant under the EUREKA-EUROSTARS programme as partner and workpackage manager. The project involves R&D within delivery technologies towards immune cells to modulate their response 2009-12: Steering group manager in the Innovation Consortia "Treg-center" working on regulatory T-cell screening models and Treg markers. Collaboration with Karolinska University Hospital, University of Southern Denmark and private companies with interest in the Treg-field 2007-10: Innovation Consortia Manager "Center for Immunomics", working on dendritic cell models and screening of immunomodulatory compounds, drugs and microorganisms involved in innate and adaptive immune responses 2007-11: Awarded a Strategic Research Grant in collaboration with DTU Nanotech on drug-delivery projects involving liposomal drug delivery to cancer and immune cells2007-present: Supervisor of PhD students and Master students
-
Eurostars Project Manager "Lipodel"Bioneer A/S Jan 2012 - Dec 2013Hørsholm, DkI was spearheading the Eurostars project "LIPODEL" from idea to setup partners as well as drafting and submitting grant proposal. The project was an innovative ambitious project between three biotech Companies and the Technical University of Denmark. The project resulted in patent applications, publications and generation of new product candidates within the immuno-oncology area.
-
Innovation Consortium Manager "Centre For Immunomics"Bioneer A/S 2009 - 2012Hørsholm, DkManagement and spearheading the Innovation Consortium "Centre for Immunomics" with participation of major pharma, biotech and ingredients companies and leading universities with interest in immunomodulation and dendritic cells. Management and communication with funding bodies and project stakeholders. The project reached major goals for both commercial and academic milestones including publications, establishment of advanced immune cell models for screening of immune modulating drugs, bacteria and probiotics, and spin-out of commercially attractive novel therapeutic targets for immunotherapy.
-
Innovation Consortium Manager "Centre For Nanostructured Polymer Surfaces"Bioneer A/S 2006 - 2008Hørsholm, DkI was managing the Innovation Consortium CNP as an innovative project between major Danish Pharma and Biomedico companies and Risø National Research Laboratory. The aim was to investigate novel surfaces supporting cell growth and differentiation, establish state-of-the art methodoligies to test for biocompatibility of surfaces and Medical devices for clinical use. The project resulted in several publications and establishment of services for the biomedical and Pharma industry.
-
Head Og Biological R&DLiplasome Pharma A/S 2001 - 2005DkResponsible for in vitro and in vivo Proof of Principle of the liposomal drug delivery technology proprietary to LiPlasome, involving sPLA2-mediated site-specific degradation og liposomes and release of the encapsulated drug.Design and experience with cancer models involving xenograft and syngenic mouse models.Involved in strategic decisions and development of new technologies like pro-drug design, liposomal design and understanding.Evaluation of cancer drugs suitable for liposomal drug delivery and as prodrug candidates using the LiPlasome technology.Evaluation and innovation to discover and develop drug delivery, site specific release and targeting technologies. Initiated NCI (National Cancer Institute) contact and collaboration and obtained NCI interest in a CRADA between LiPlasome and NCI -
PhdLeo Pharma/Danish Cancer Society 1998 - 2001PhD project; research focused on Vitamin D and analogues analyzing the effect on cell cycle regulation. Supervised by Professor, Dr Med Jiri Bartek, and Head of Section, PhD, Mogens Winkel MadsenGained experience from a world class leading laboratory at the Danish Cancer Society, and from the pharmaceutical industry (LEO-Pharma)
-
Master Of Science StudentThe Danish Cancer Society 1994 - 1997København Ø, DkMaster studies at Jiri Barteks group at the Danish Cancer Society. Main research area was regulation of the cell cycle, involving mainly CDK regulation and function -
Elite Athlete In CyclingDanish National Road Racing Team Jan 1985 - Dec 1989Elite athlete and part of the National Danish road racing team in cycling. Twice Danish Champion and Danish Record holder in road racing. Participated in a number of championships and key races and criteriums.
Simon Skjøde Jensen Skills
Simon Skjøde Jensen Education Details
-
Københavns Universitet - University Of CopenhagenCell Biology/Molecular Biology -
Syddansk Universitet - University Of Southern DenmarkBiotechnology
-
Harvard Business School Executive EducationCourse On Leading Breakthrough Innovation
Frequently Asked Questions about Simon Skjøde Jensen
What company does Simon Skjøde Jensen work for?
Simon Skjøde Jensen works for Monta Biosciences
What is Simon Skjøde Jensen's role at the current company?
Simon Skjøde Jensen's current role is CEO at MonTa Biosciences.
What is Simon Skjøde Jensen's email address?
Simon Skjøde Jensen's email address is ss****@****neer.dk
What schools did Simon Skjøde Jensen attend?
Simon Skjøde Jensen attended Københavns Universitet - University Of Copenhagen, Syddansk Universitet - University Of Southern Denmark, Harvard Business School Executive Education.
What are some of Simon Skjøde Jensen's interests?
Simon Skjøde Jensen has interest in Icehockey, Kayaking, Floorball, Skiing, Modern Art And Design, Cycling, Hiking, Mountain Biking With My Team (Tema Kgb), Freind And Family.
What skills is Simon Skjøde Jensen known for?
Simon Skjøde Jensen has skills like Life Sciences, Cell, In Vitro, Cell Biology, R&d, Cancer, In Vivo, Screening, Drug Delivery, Cell Culture, Biotechnology, Immunology.
Free Chrome Extension
Find emails, phones & company data instantly
Aero Online
Your AI prospecting assistant
Select data to include:
0 records × $0.02 per record
Download 750 million emails and 100 million phone numbers
Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.
Start your free trial